2012 ICD-9-CM Diagnosis Code 162.9. Malignant neoplasm of bronchus and lung, unspecified. Short description: Mal neo bronch/lung NOS. ICD-9-CM 162.9 is a billable medical code that can be used to indicate a diagnosis on a reimbursement claim, however, 162.9 should only be used for claims with a date of service on or before September 30, 2015.
Malignant neoplasm of bronchus and lung, unspecified Short description: Mal neo bronch/lung NOS. ICD-9-CM 162.9 is a billable medical code that can be used to indicate a diagnosis on a reimbursement claim, however, 162.9 should only be used for claims with a date of service on or before September 30, 2015.
162.9 is a legacy non-billable code used to specify a medical diagnosis of malignant neoplasm of bronchus and lung, unspecified. This code was replaced on September 30, 2015 by its ICD-10 equivalent. Adenocarcinoma of lung, stage I
2018/2019 ICD-10-CM Diagnosis Code C78.00. Secondary malignant neoplasm of unspecified lung. C78.00 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
Basic DifferencesLung NeoplasmTopography CodeBehavior CodeMetastatic neoplasm of the lung (such as metastatic seminoma from the testis)C34.9M-9061/6In situ neoplasm of the lung (such as squamous carcinoma in situ)C34.9M-8070/2Benign neoplasm of lung (such as adenoma)C34.9M-8140/02 more rows
The 2022 edition of ICD-10-CM C79. 9 became effective on October 1, 2021. This is the American ICD-10-CM version of C79.
C34. 90 - Malignant neoplasm of unspecified part of unspecified bronchus or lung | ICD-10-CM.
ICD-9-CM Diagnosis Code 199.1 : Other malignant neoplasm without specification of site.
ICD-10 code C78. 00 for Secondary malignant neoplasm of unspecified lung is a medical classification as listed by WHO under the range - Malignant neoplasms .
Squamous cell carcinoma - a very common form of nonmelanoma skin cancer that originates in the squamous cells - becomes metastatic when it spreads (metastasizes) beyond the primary cancer site and affects other areas of the body.
C34. 90 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM C34. 90 became effective on October 1, 2021.
90 Malignant neoplasm of unspecified part of unspecified bronchus or lung.
Associated ICD-10-CM CodesMalignant neoplasm of bronchus and lungC34.90Malignant neoplasm of unspecified part of unspecified bronchus or lungC34.91Malignant neoplasm of unspecified part of right bronchus or lungC34.92Malignant neoplasm of unspecified part of left bronchus or lung18 more rows
Code C80. 1, Malignant (primary) neoplasm, unspecified, equates to Cancer, unspecified.
ICD-10 Code for Squamous cell carcinoma of skin, unspecified- C44. 92- Codify by AAPC.
A malignant tumor at the original site of growth. [ from NCI]
If the site of the primary cancer is not documented, the coder will assign a code for the metastasis first, followed by C80. 1 malignant (primary) neoplasm, unspecified. For example, if the patient was being treated for metastatic bone cancer, but the primary malignancy site is not documented, assign C79.
C80. 1 - Malignant (primary) neoplasm, unspecified | ICD-10-CM.
(meh-TAS-tuh-size) To spread from one part of the body to another. When cancer cells metastasize and form secondary tumors, the cells in the metastatic tumor are like those in the original (primary) tumor.
Z85. 3 can be billed as a primary diagnosis if that is the reason for the visit, but follow up after completed treatment for cancer should coded as Z08 as the primary diagnosis.
Malignant neoplasm of bronchus and lung, unspecified 1 Short description: Mal neo bronch/lung NOS. 2 ICD-9-CM 162.9 is a billable medical code that can be used to indicate a diagnosis on a reimbursement claim, however, 162.9 should only be used for claims with a date of service on or before September 30, 2015. For claims with a date of service on or after October 1, 2015, use an equivalent ICD-10-CM code (or codes). 3 You are viewing the 2012 version of ICD-9-CM 162.9. 4 More recent version (s) of ICD-9-CM 162.9: 2013 2014 2015.
Cancer of the lung, squamous cell, stage 1. Cancer of the lung, squamous cell, stage 2. Cancer of the lung, squamous cell, stage 3. Cancer of the lung, squamous cell, stage 4. Cancer of the right lung, large cell. Cancer of the right lung, squamous cell. Cancer, left lung. Cancer, lung, non small cell.
T3: Lung tumor of any size in the main bronchus < 2 cm distal to the carina but without involvement of the carina
Malignant tumor involving an organ by direct extension from uterine cervix. Malignant tumor involving an organ by direct extension from uterus. Malignant tumor involving an organ by direct extension from vagina. Malignant tumor involving an organ by separate metastasis from bladder.
Malignant neoplasm. Malignant neoplasm associated with AIDS. Malignant neoplastic disease. Malignant neoplastic disease in pregnancy. Malignant neoplastic disease postpartum. Malignant tumor involving an organ by direct extension from bladder. Malignant tumor involving an organ by direct extension from endometrium.
ICD-9-CM 199.1 is a billable medical code that can be used to indicate a diagnosis on a reimbursement claim, however, 199.1 should only be used for claims with a date of service on or before September 30, 2015. For claims with a date of service on or after October 1, 2015, use an equivalent ICD-10-CM code (or codes).
162.9 is a legacy non-billable code used to specify a medical diagnosis of malignant neoplasm of bronchus and lung, unspecified. This code was replaced on September 30, 2015 by its ICD-10 equivalent.
Squamous cell carcinoma of lung, TNM stage 1. Squamous cell carcinoma of lung, TNM stage 2. Squamous cell carcinoma of lung, TNM stage 3. Squamous cell carcinoma of lung, TNM stage 4. T3: Lung tumor of any size in the main bronchus < 2 cm distal to the carina but without involvement of the carina.
T4: Lung tumor of any size with a malignant pleural effusion
NEC "Not elsewhere classifiable" - This abbreviation in the Alphabetic Index represents "other specified". When a specific code is not available for a condition, the Alphabetic Index directs the coder to the "other specified” code in the Tabular List.
Doctors diagnose lung cancer using a physical exam, imaging, and lab tests. Treatment depends on the type, stage, and how advanced it is. Treatments include surgery, chemotherapy, radiation therapy, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells.
Type 1 Excludes Notes - A type 1 Excludes note is a pure excludes note. It means "NOT CODED HERE!" An Excludes1 note indicates that the code excluded should never be used at the same time as the code above the Excludes1 note. An Excludes1 is used when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
197.0 is a legacy non-billable code used to specify a medical diagnosis of secondary malignant neoplasm of lung. This code was replaced on September 30, 2015 by its ICD-10 equivalent.
Code also note - A "code also" note instructs that two codes may be required to fully describe a condition, but this note does not provide sequencing direction.
NEC "Not elsewhere classifiable" - This abbreviation in the Alphabetic Index represents "other specified". When a specific code is not available for a condition, the Alphabetic Index directs the coder to the "other specified” code in the Tabular List.
Type 1 Excludes Notes - A type 1 Excludes note is a pure excludes note. It means "NOT CODED HERE!" An Excludes1 note indicates that the code excluded should never be used at the same time as the code above the Excludes1 note. An Excludes1 is used when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere.
The 2022 edition of ICD-10-CM C78.00 became effective on October 1, 2021.